STOCK DUELS
AstraZeneca vs GSK - Official head-to-head comparisons for widely followed pairs.
Official Stock Duel · AZN/GSKPublished
AstraZeneca vs GSK
Compares AstraZeneca and GSK across growth, profitability, cash generation, valuation and balance-sheet signals.
Left side
AZN.LSE
Right side
GSK.LSE
Comparison categories
6
Generated: Sep 12, 2026, 04:31 AM
Data as of: 2026-09-11
Stock Duels· 23 analyses
Official head-to-head comparisons for widely followed pairs.
Head-to-Head
AZN
AstraZeneca PLC
2VS4
metrics
GSK
GSK plc
9.32%
Sales Growth
4.97%
22.78%
Return on Equity (ROE)
29.73%
15.02%
Return on Invested Capital (ROIC)
23.04%
$8.4B
Free Cash Flow
$7.6B
23.71
Price to Earnings (P/E)
14.96
13.43
EV/EBITDA
7.97
Datafin’s View
Britain’s pharma giants: AstraZeneca’s oncology momentum against GSK’s vaccines-and-medicines balance.
Both draw from the same market; the difference is the quality of the pipeline and the pace of growth. AstraZeneca carries clearer oncology momentum and a richer late-stage pipeline, while GSK balances vaccines and medicines at a more cautious valuation — growth against steadiness.
This analysis is for informational purposes only and is not investment advice; it is a repeatable research starting point using the same rules.
Factor Profile
AZN.LSE and GSK.LSE are compared inside each metric family.
Results
Latest published or live-generated results from the official Datafin analysis.
| # | Stock | Winner | Sales Growth | Return on Equity(ROE) | Return on Invested Capital(ROIC) | Free Cash Flow | Price to Earnings(P/E) | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 🇬🇧 | AZN.LSE AstraZeneca PLC | - | 9.32% | 22.78% | 15.02% | $8.4B | 23.71 | 13.43 |
| 2 | 🇬🇧 | GSK.LSE GSK plc | 4.97% | 29.73% | 23.04% | $7.6B | 14.96 | 7.97 |
1🇬🇧
AZN.LSE
AstraZeneca PLC
- Sales Growth
- 9.32%
- Return on Equity(ROE)
- 22.78%
- Return on Invested Capital(ROIC)
- 15.02%
- Free Cash Flow
- $8.4B
- Price to Earnings(P/E)
- 23.71
- EV/EBITDA
- 13.43
2🇬🇧
GSK.LSE
GSK plc
- Sales Growth
- 4.97%
- Return on Equity(ROE)
- 29.73%
- Return on Invested Capital(ROIC)
- 23.04%
- Free Cash Flow
- $7.6B
- Price to Earnings(P/E)
- 14.96
- EV/EBITDA
- 7.97
Methodology
Revenue Growthhigher is better
ROEhigher is better
ROIChigher is better
Free Cash Flowhigher is better
P/Elower is better
EV/EBITDAlower is better
Last 5 Updates
Sep 12, 2026, 04:31 AM2 companies
List unchanged (refreshed).
Aug 31, 2026, 04:32 AM2 companies
List unchanged (refreshed).
Aug 20, 2026, 04:31 AM2 companies
List unchanged (refreshed).
Aug 9, 2026, 04:30 AM2 companies
Entered:AZN.LSE
Exited:AZN.ST
Jul 29, 2026, 04:30 AM2 companies
List unchanged (refreshed).